[go: up one dir, main page]

PE20181350A1 - Inhibidores marcados con 18f mejorados de antigeno de membrana especifico de prostata (psma) y su uso como agentes de diagnostico por imagenes para el cancer de prostata - Google Patents

Inhibidores marcados con 18f mejorados de antigeno de membrana especifico de prostata (psma) y su uso como agentes de diagnostico por imagenes para el cancer de prostata

Info

Publication number
PE20181350A1
PE20181350A1 PE2018000482A PE2018000482A PE20181350A1 PE 20181350 A1 PE20181350 A1 PE 20181350A1 PE 2018000482 A PE2018000482 A PE 2018000482A PE 2018000482 A PE2018000482 A PE 2018000482A PE 20181350 A1 PE20181350 A1 PE 20181350A1
Authority
PE
Peru
Prior art keywords
prostate
psma
inhibitors
marked
enhanced
Prior art date
Application number
PE2018000482A
Other languages
English (en)
Inventor
Uwe Albert Haberkorn
Frederik Lars Giesel
Matthias Philipp Dieter Eder
Jens Cardinale
Martina Benesova
Christian Martin Schafer
Klaus Kopka
Ulrike Bauder-Wust
Michael Eisenhut
Original Assignee
Deutsches Krebsforsch
Univ Heidelberg Ruprecht Karls
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforsch, Univ Heidelberg Ruprecht Karls filed Critical Deutsches Krebsforsch
Publication of PE20181350A1 publication Critical patent/PE20181350A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • G01N33/57555—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta referido a compuestos de formula (I), donde: i, j es 0 o 1; m es 1 - 5; n es 0 - 3; R es H, CH3; AS es aminoacido natural o artificial; Z es -CO2H, -SO2H, -SO3H, entre otros; X es naftilo, fenilo, bifenilo, entre otros; y es arilo, alquilarilo, ciclopentilo, entre otros; estos compuestos se usan en el campo de los radiofarmacos, en medicina nuclear, como marcadores y, en este caso, como agentes de diagnostico por imagenes para los distintos estadios del cancer de prostata. Tambien se refiere a una composicion farmaceutica, un profarmaco, sal o ester de estos compuestos, y un portador aceptable desde el punto de vista farmaceutico
PE2018000482A 2015-09-30 2016-09-19 Inhibidores marcados con 18f mejorados de antigeno de membrana especifico de prostata (psma) y su uso como agentes de diagnostico por imagenes para el cancer de prostata PE20181350A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15002800 2015-09-30
EP16164090 2016-04-06
EP16182764 2016-08-04

Publications (1)

Publication Number Publication Date
PE20181350A1 true PE20181350A1 (es) 2018-08-22

Family

ID=57121178

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000482A PE20181350A1 (es) 2015-09-30 2016-09-19 Inhibidores marcados con 18f mejorados de antigeno de membrana especifico de prostata (psma) y su uso como agentes de diagnostico por imagenes para el cancer de prostata

Country Status (31)

Country Link
US (3) US10815200B2 (es)
EP (2) EP3805250A1 (es)
JP (1) JP6824971B2 (es)
KR (1) KR102233726B1 (es)
CN (1) CN108026144B (es)
AU (1) AU2016333334B2 (es)
BR (1) BR112018005899A2 (es)
CL (1) CL2018000604A1 (es)
CO (1) CO2018003726A2 (es)
CU (1) CU24524B1 (es)
CY (1) CY1123790T1 (es)
DK (1) DK3356385T3 (es)
EA (1) EA037512B1 (es)
ES (1) ES2844586T3 (es)
GE (2) GEAP202014748A (es)
HR (1) HRP20210183T1 (es)
HU (1) HUE053064T2 (es)
IL (1) IL258378B (es)
LT (1) LT3356385T (es)
MX (1) MX390931B (es)
MY (1) MY197061A (es)
NZ (1) NZ739770A (es)
PE (1) PE20181350A1 (es)
PH (1) PH12018500701B1 (es)
PL (1) PL3356385T3 (es)
RS (1) RS61394B1 (es)
SA (1) SA518391121B1 (es)
SI (1) SI3356385T1 (es)
TN (1) TN2018000089A1 (es)
WO (1) WO2017054907A1 (es)
ZA (1) ZA201801024B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017054907A1 (en) * 2015-09-30 2017-04-06 Deutsches Krebsforschungszentrum 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer
CN109803973B (zh) 2016-08-10 2022-05-24 癌靶技术有限责任公司 螯合psma抑制剂
ES3041039T3 (en) 2016-10-27 2025-11-06 Progenics Pharm Inc Network for medical image analysis, decision support system, and related graphical user interface (gui) applications
DE102016122273B4 (de) 2016-11-18 2018-06-21 Abx Advanced Biochemical Compounds Gmbh Präkursoren für die Radiofluorierung
CA3043619A1 (en) * 2016-11-23 2018-05-31 Cancer Targeted Technology Llc Albumin-binding psma inhibitors
EP4564288A3 (en) 2019-04-24 2025-09-17 Progenics Pharmaceuticals, Inc. Systems and methods for automated and interactive analysis of bone scan images for detection of metastases
CN110272468B (zh) * 2019-05-14 2020-12-08 上海益泰医药科技有限公司 一种前列腺特异性膜抗原小分子抑制剂及其放射性核素配合物的制备及应用
US12417533B2 (en) 2019-09-27 2025-09-16 Progenics Pharmaceuticals, Inc. Systems and methods for artificial intelligence-based image analysis for cancer assessment
CN111253465A (zh) * 2020-03-03 2020-06-09 复旦大学附属肿瘤医院 一种psma结合剂及其用途
WO2022167681A1 (en) 2021-02-08 2022-08-11 Stichting Radboud Universitair Medisch Centrum Psma-targeting ligands for multimodal applications
CN118265718A (zh) * 2021-07-30 2024-06-28 国立大学法人大阪大学 放射性标记化合物及其用途
JP2024532475A (ja) * 2021-09-01 2024-09-05 天津恒瑞医薬有限公司 前立腺特異的膜抗原の阻害剤及びその医薬的使用
CN118344391A (zh) * 2023-01-13 2024-07-16 浙江普利药业有限公司 一种新的用于硼中子捕获疗法的含硼化合物
WO2025041103A1 (en) * 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Psma targeting ligands and methods of use

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5095050B2 (ja) 1999-04-28 2012-12-12 ジョージタウン ユニバーシティー 代謝調節型グルタミン酸受容体のリガンド、及び、ＮＡＡＬＡＤａｓｅの阻害剤
EP1409017A4 (en) 2001-06-25 2006-05-24 Drug Innovation & Design Inc CELL TARGETING INVOLVING THE RECONNAISSANCE OF EXPONENTIAL FORMS, COMPOSITIONS, METHODS AND ANTICANCER APPLICATIONS
EP1472541B1 (en) 2002-01-10 2009-09-16 The Johns Hopkins University Imaging agents and methods of imaging naaladase of psma
WO2006093991A1 (en) 2005-03-02 2006-09-08 The Cleveland Clinic Foundation Compounds which bind psma and uses thereof
EP2087337A4 (en) 2006-11-03 2010-09-08 Purdue Research Foundation METHOD AND DEVICE FOR EX-VIVO FLOW CYTOMETRY
CN103922998A (zh) 2006-11-08 2014-07-16 分子制药洞察公司 谷氨酸的异质二聚体
WO2008088648A2 (en) 2007-01-11 2008-07-24 Immunomedics, Inc. Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
US9044468B2 (en) 2007-06-26 2015-06-02 The Johns Hopkins University Labeled inhibitors of prostate specific membrane antigen (PSMA), biological evaluation, and use as imaging agents
NZ583931A (en) * 2007-08-17 2012-06-29 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
EP2644594B1 (en) 2007-09-28 2017-08-23 Pfizer Inc Cancer Cell Targeting Using Nanoparticles
WO2009070302A1 (en) 2007-11-30 2009-06-04 The Johns Hopkins University Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer
US8562945B2 (en) 2008-01-09 2013-10-22 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof
JP2011509304A (ja) 2008-01-09 2011-03-24 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 炭酸脱水酵素ｉｘの阻害剤
DK3222615T3 (da) 2008-08-01 2022-06-20 Univ Johns Hopkins Psma-bindende stoffer og anvendelser deraf
AU2009322171A1 (en) 2008-12-05 2011-06-30 Molecular Insight Pharmaceuticals, Inc. CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer
HUE068042T2 (hu) 2009-03-19 2024-12-28 Univ Johns Hopkins PSMA-targetáló vegyületek és alkalmazásaik
GB0905438D0 (en) 2009-03-30 2009-05-13 Ge Healthcare Ltd Radiolabelling reagents and methods
EP2338892A1 (en) * 2009-12-18 2011-06-29 Bayer Schering Pharma Aktiengesellschaft Prostate specific membrane antigen inhibitors
GB201020314D0 (en) 2010-12-01 2011-01-12 Ge Healthcare Ltd Apoptosis pet imaging agents
US9687572B2 (en) 2010-12-06 2017-06-27 Molecular Insight Pharmaceuticals, Inc. PSMA-targeted dendrimers
WO2012166923A2 (en) 2011-05-31 2012-12-06 Bind Biosciences Drug loaded polymeric nanoparticles and methods of making and using same
US8926944B2 (en) 2011-08-05 2015-01-06 Molecular Insight Pharmaceuticals Radiolabeled prostate specific membrane antigen inhibitors
WO2013028664A1 (en) * 2011-08-22 2013-02-28 Siemens Medical Solutions Usa, Inc. Psma imaging agents
AU2013369982B2 (en) 2012-12-28 2016-11-17 Tva (Abc), Llc Targeted conjugates encapsulated in particles and formulations thereof
EP2958596B1 (en) 2013-02-15 2019-12-04 Case Western Reserve University Psma ligands and uses thereof
WO2015004029A1 (en) 2013-07-08 2015-01-15 Technische Universität München 18f-labeling of aromatic and heteroaromatic molecules with unprotected carboxylic acid groups
US10406246B2 (en) * 2013-10-17 2019-09-10 Deutsches Kresbsforschungszentrum Double-labeled probe for molecular imaging and use thereof
US20150110814A1 (en) 2013-10-18 2015-04-23 Psma Development Company, Llc Combination therapies with psma ligand conjugates
TN2016000137A1 (en) 2013-10-18 2017-10-06 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer.
ES3013992T3 (en) 2013-11-14 2025-04-16 Endocyte Inc Compounds for positron emission tomography
US11124845B2 (en) 2014-03-18 2021-09-21 The Johns Hopkins University PSMA-based molecular-genetic reporter system
EP3536345A1 (en) 2014-05-06 2019-09-11 The Johns Hopkins University Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy
WO2016030329A1 (en) 2014-08-24 2016-03-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer
WO2016040179A1 (en) 2014-09-08 2016-03-17 Molecular Insight Pharmaceuticals, Inc. Organ protection in psma-targeted radionuclide therapy of prostate cancer
EP3209336B1 (en) * 2014-10-20 2019-12-11 Deutsches Krebsforschungszentrum 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP3011976A1 (en) 2014-10-20 2016-04-27 Deutsches Krebsforschungszentrum 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents
US10736974B2 (en) 2014-10-22 2020-08-11 The Johns Hopkins University Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy
WO2017054907A1 (en) * 2015-09-30 2017-04-06 Deutsches Krebsforschungszentrum 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer

Also Published As

Publication number Publication date
CA2996330A1 (en) 2017-04-06
CN108026144A (zh) 2018-05-11
BR112018005899A2 (pt) 2018-10-16
JP6824971B2 (ja) 2021-02-03
PL3356385T3 (pl) 2021-06-28
ZA201801024B (en) 2019-06-26
KR102233726B1 (ko) 2021-03-31
IL258378B (en) 2021-03-25
GEAP202014748A (en) 2020-01-27
CL2018000604A1 (es) 2019-03-29
JP2018531243A (ja) 2018-10-25
CN108026144B (zh) 2022-02-01
IL258378A (en) 2018-05-31
EP3356385A1 (en) 2018-08-08
LT3356385T (lt) 2021-02-25
US20180194729A1 (en) 2018-07-12
EP3805250A1 (en) 2021-04-14
PH12018500701B1 (en) 2022-11-16
NZ739770A (en) 2019-07-26
AU2016333334B2 (en) 2019-07-25
MX390931B (es) 2025-03-21
MY197061A (en) 2023-05-23
RS61394B1 (sr) 2021-02-26
EA201890282A1 (ru) 2018-09-28
GEP20207106B (en) 2020-05-11
ES2844586T3 (es) 2021-07-22
HUE053064T2 (hu) 2021-06-28
CU20180030A7 (es) 2018-08-06
TN2018000089A1 (en) 2019-07-08
CO2018003726A2 (es) 2018-07-19
SA518391121B1 (ar) 2021-05-30
EP3356385B1 (en) 2020-11-11
SI3356385T1 (sl) 2021-04-30
HRP20210183T1 (hr) 2021-04-30
US20230295092A1 (en) 2023-09-21
PH12018500701A1 (en) 2018-10-15
EA037512B1 (ru) 2021-04-06
DK3356385T3 (da) 2021-02-15
CY1123790T1 (el) 2022-05-27
WO2017054907A1 (en) 2017-04-06
US10815200B2 (en) 2020-10-27
US20210053922A1 (en) 2021-02-25
KR20180058822A (ko) 2018-06-01
AU2016333334A1 (en) 2018-03-08
US12054458B2 (en) 2024-08-06
MX2018004050A (es) 2018-08-01
CU24524B1 (es) 2021-06-08

Similar Documents

Publication Publication Date Title
PE20181350A1 (es) Inhibidores marcados con 18f mejorados de antigeno de membrana especifico de prostata (psma) y su uso como agentes de diagnostico por imagenes para el cancer de prostata
CO2019011762A2 (es) Compuestos que inhiben la proteína mcl-1
CR20170116A (es) Compuestos que inhiben la proteina mcl-1
DOP2011000264A (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
MX2021008977A (es) Inhibidores marcados de antigeno prostatico especifico de membrama (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata.
UY38096A (es) Inhibidores de arginasa y sus métodos de uso
CL2018001146A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
MX383051B (es) Compuestos que inhiben eif4a y métodos relacionados a los mismos.
UY33491A (es) ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?.
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
UY33500A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
CO2018004933A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
AR079050A1 (es) Compuestos benzoimidazolicos y sus usos
CL2017000682A1 (es) Compuestos novedosos de imidazopiridazina y su uso.
MX389244B (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
CR20170468A (es) Compuestos novedosos
CU20190042A7 (es) Compuestos derivados de naftiridinona
UY38786A (es) Agonistas de receptores tipo toll
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
MX384392B (es) Moduladores heterocíclicos de la síntesis de lípidos para su uso contra el cáncer e infecciones virales.
AR086803A1 (es) Derivados de oxazetidinas, composiciones farmaceuticas y cosmeticas que los contienen y uso de los mismos para tratar enfermedades dermatologicas fundamentalmente, y del aparato respiratorio, digestivo y cardiovascular, entre otras
AR088735A1 (es) Compuestos de tienopirimidina que son inhibidores de canal de potasio
UY33806A (es) ?compuestos novedosos de imidazoquinolina, composiciones que los contienen y su uso en el tratamiento de enfermedades mediadas por tlr7?
CO2019012386A2 (es) Formulación de inhibidor de stat3